A patient with BRAF V600E-mutant microsatellite-stable metastatic colorectal cancer achieved a prolonged response to pembrolizumab following a dynamic increase in tumor mutational burden. (The Oncologist)
Prolonged Response to Pembrolizumab in BRAF V600E MSS Colorectal Cancer
The CRC Digest